XIMEPEG (macrogol 4 000 + electrolytes + simeticone)

GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Oct 24 2018

Reason for request

Inclusion

High clinical benefit in colonic lavage, though no demonstrated clinical advantage over other available preparations.

 

  • XIMEPEG has been granted marketing authorisation for intestinal lavage prior to an examination requiring a clean intestine, such as endoscopic or radiological exploration.

  • Its administration requires drinking 2 litres of water. After examination, patients should be encouraged to drink a large volume of liquid (at least 1 L) to compensate for the liquid loss incurred during preparation.

  • Its equivalence in terms of success of XIMEPEG colonic preparation compared to other relevant comparators (macrogol and electrolyte-based solution and MOVIPREP) has been established by two studies.

  • No data are available to support an improvement in quality-of-life nor an impact of colonic lavage, for example on the number of neoplastic lesions detected, relative to the comparators.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-